Architecting Governance for Military Human-Enhancement Programs
The danger is not only the hormone test itself – it’s the architecture we build around it.
A recent proposal in the U.S. Department of Defense to institute routine testosterone screening and optional hormone replacement for service members is being debated as a medical and cultural intervention. Stripped to essentials: an organization is proposing wide-scale biometric measurement with treatment decisions tied to those measurements. That raises questions that technologists and enterprise architects should recognize immediately – because the same systemic design choices apply whether you’re instrumenting servers, supply chains, or human bodies.
Why this matters to architects and leaders
I see three intersecting risks whenever an institution operationalizes biological metrics at scale: measurement fallibility, feedback-driven behaviour change, and governance gaps.
-
Measurement fallibility: Biological signals are noisy, context-dependent, and often non-deterministic. Testosterone fluctuates by time of day, assay method, recent stress or illness, and individual baseline. Treating single snapshots as deterministic inputs to large-scale interventions is analogous to acting on a single log entry to reconfigure a production system – you will get false positives and expensive remediation cascades.
-
Goodhart and operational incentives: “If you measure it, you will manage it.” Turn a hormone level into a performance metric and you change behavior – sometimes in perverse ways. Individuals and units may game measurement, avoid testing, or pursue short-term gains that hurt long-term health. This is the classic Goodhart problem applied to human physiology.
-
Governance and consent: Biometric and health data are high-impact, highly sensitive. Architects must design for privacy, explainability, informed consent, and the possibility of revocation. Equally important: clinical validity and a clear causal chain linking intervention to meaningful outcomes must exist before scaling.
A pragmatic architecture for any biometric program
If an enterprise – public sector or private – decides to pursue population-level physiologic monitoring, here is the roadmap I would insist on as an architect:
-
Define outcomes, not proxies. Are you optimising for battlefield survivability, reduced attrition, reduced morbidity, or something else? Each outcome requires different measurements and trial designs.
-
Validate measurements. Standardize assays, control for sampling conditions (time-of-day, fasting state, recent exertion), and quantify measurement error. Treat the laboratory pipeline as a critical, versioned component with SLAs and test harnesses.
-
Start small with rigorous evaluation. Pilot with randomized controlled designs where ethical and feasible. Measure both intended benefits and unintended harms (mental health, incidence of side-effects, equity impacts).
-
Architect for consent and data stewardship. Use role-based access, encryption-at-rest and in-transit, auditable consent records, and time-bounded retention. Ensure data portability and clear deletion semantics.
-
Multi-disciplinary governance. Clinical medicine, ethics, legal, operations, and IT must share decision rights. Clinical inputs should be peer-reviewed and publicly auditable where national security allows.
-
Monitor behavioural feedback loops. Instrument for gaming, dropout, and workplace culture metrics. Create safe channels for whistleblowing and independent oversight.
What this teaches technologists and CTOs
The thrust of this debate is a reminder: instrumenting humans is categorically different from instrumenting machines. Engineers are comfortable with telemetry, thresholds, and automated responses – but biology resists simple thresholds. When technology and clinical practice intersect, the bar for evidence, transparency, and governance must rise.
For leaders building any large-scale biometric or health-data program, the strategic trade-offs are familiar: speed vs. safety, short-term gains vs. long-term trust, centralization vs. distributed clinical judgment. The right architecture protects individual rights while enabling measurable, defensible operational improvements.
Takeaways
- Don’t treat single physiological metrics as definitive inputs to policy.
- Invest in assay standardization and contextual metadata (time, activity, stressors).
- Pilot with clinical rigor and measure harms as carefully as benefits.
- Build strong privacy, consent, and audit mechanisms into the data architecture.
- Establish multi-disciplinary governance with independent oversight.
Closing thought
Measurement without humility breeds brittle systems. When institutions decide to instrument human bodies, they must design systems that acknowledge uncertainty, protect consent, and prioritise long-term trust over short-term signals.
About the Author: Sanjeev Sarma is the Founder Director and Chief Software Architect at Webx Technologies. With a core focus on Generative AI integration, Cloud-Native Scalability, and Enterprise Software Architecture, he has spent over two decades driving digital transformation across Northeast India and beyond. Beyond his corporate leadership, Sanjeev is deeply invested in shaping the future of the IT industry. He serves as an Industry Expert on the Board of Studies for Assam Don Bosco University’s School of Technology, advises state technology committees, and actively mentors emerging tech startups at STPI. He brings a unique, dual perspective of high-level enterprise execution and future-ready academic curriculum development.
